For security purposes
FOR SECURITY PURPOSES - because Internet Explorer is no longer supported by Microsoft, we suggest that you interact with our secure site through one of our supported browsers - Google Chrome, Firefox, or MS Edge. If you continue to use this website with Internet Explorer you do so at your own risk and you may encounter problems.
search
Documents
Released N-Glycan Analysis of Infliximab-dyyb including Sialylated Glycans using a Biozen 2.6 μm Glycan Column
Glycosylation of biologics during recombinant synthesis must be fully characterized for therapeutic development. Employing a Biozen Glycan LC column for a HILIC-mode separation of released N-glycans is an effective protocol.
Released N-Glycan Analysis of Infliximab-dyyb including Sialylated Glycans using a Biozen 2.6 μm Glycan Column
Glycosylation of biologics during recombinant synthesis must be fully characterized for therapeutic development. Employing a Biozen Glycan LC column for a HILIC-mode separation of released N-glycans is an effective protocol.
Document Type:
Technical Notes
Target Industries:
Biopharmaceutical Analysis, Pharmaceutical
Techniques:
HPLC, HILIC Chromatography, Sample Preparation
Brands:
Biozen LC, Biozen SPE
Separation Modes:
HILIC
Phases:
Biozen-Glycan
save_alt Download
favorite_border
Phenomenex logo
Headquarters
411 Madrid Avenue, Torrance, CA 90501
t: (310) 212-0555 f: (310) 328-7768

OUR PRODUCTS AND SERVICES

Products

Techniques

Industries

OUR COMPANY 

About Phenomenex

Our Humanity

Our People

Blog

Danaher Life Sciences

Stay up to date on the latest from Phenomenex
Iso logo
Terms and Conditions Privacy Statement Quality Policy Terms of Use Trademarks CA Supply Chains Act CA Consumer Privacy Act Cookie Policy Cookie Settings © 2023 Phenomenex Inc. All rights reserved.